These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. A pilot study on EORTC or PERCIST for the prediction of progression-free survival with nivolumab therapy in advanced or metastatic gastric cancers: A STROBE-compliant article. Nakajo M, Kitajima K, Toriihara A, Arigami T, Daisaki H, Nakamura A, Ohtsuka T, Miwa H, Yoshiura T. Medicine (Baltimore); 2021 Apr 16; 100(15):e25494. PubMed ID: 33847661 [Abstract] [Full Text] [Related]
7. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab. Skougaard K, Nielsen D, Jensen BV, Hendel HW. J Nucl Med; 2013 Jul 16; 54(7):1026-31. PubMed ID: 23572497 [Abstract] [Full Text] [Related]
10. The prognostic value of [18F]FDG PET/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: comparison of different metabolic criteria. Sachpekidis C, Weru V, Kopp-Schneider A, Hassel JC, Dimitrakopoulou-Strauss A. Eur J Nucl Med Mol Imaging; 2023 Jul 16; 50(9):2699-2714. PubMed ID: 37099131 [Abstract] [Full Text] [Related]
12. 18F-FDG PET/CT for monitoring anti-PD-1 therapy in patients with non-small cell lung cancer using SUV harmonization of results obtained with various types of PET/CT scanners used at different centers. Ito K, Kitajima K, Toriihara A, Ishibashi M, Nakahara T, Daisaki H, Ohe Y, Honda R, Kijima T, Hasegawa S, Nakajo M. Ann Nucl Med; 2021 Nov 16; 35(11):1253-1263. PubMed ID: 34370219 [Abstract] [Full Text] [Related]
14. Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma. Cho SY, Lipson EJ, Im HJ, Rowe SP, Gonzalez EM, Blackford A, Chirindel A, Pardoll DM, Topalian SL, Wahl RL. J Nucl Med; 2017 Sep 16; 58(9):1421-1428. PubMed ID: 28360208 [Abstract] [Full Text] [Related]
15. Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria. Ziai D, Wagner T, El Badaoui A, Hitzel A, Woillard JB, Melloni B, Monteil J. Cancer Imaging; 2013 Mar 05; 13(1):73-80. PubMed ID: 23466871 [Abstract] [Full Text] [Related]
16. Agreement Between the European Organization for Research and Treatment of Cancer and Positron Emission Tomography Response Criteria in Solid Tumors in Evaluating Treatment Response in Solid Malignant Tumors. Nasir Z, Mahmood T, Adel H, Nausheen S, Hamid S, Sattar A, Manohar M. Cureus; 2019 Aug 18; 11(8):e5422. PubMed ID: 31632874 [Abstract] [Full Text] [Related]
17. Comparison Between 18F-FDG PET-Based and CT-Based Criteria in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. Rossi G, Bauckneht M, Genova C, Rijavec E, Biello F, Mennella S, Dal Bello MG, Cittadini G, Bruzzi P, Piva R, Ceriani V, Sambuceti G, Lopci E, Morbelli S, Grossi F. J Nucl Med; 2020 Jul 18; 61(7):990-998. PubMed ID: 31806768 [Abstract] [Full Text] [Related]